Skip to main content
SpringerLink
Log in

Acarbose

An Update of Its Therapeutic Use in Diabetes Treatment

  • Review Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Oral antidiabetic drugs are becoming increasingly important as rates of type 2 diabetes, uncontrolled by dietary intervention alone, increase around the world. Therapeutic agents that target the early stages of type 2 diabetes, such as the α-glucosidase enzyme inhibitor acarbose, which reduces postprandial hyperglycaemia and hyperinsulinaemia, now have a more prominent role to play in diabetes management in view of increasing evidence that the postprandial state is an important contributing factor to the development of atherosclerosis.

This review provides an update on the role of acarbose in present-day diabetes care. Acarbose is a first-line treatment for newly diagnosed patients with type 2 diabetes, those who have high postprandial blood glucose and for patients where dietary treatment alone provides inadequate glycaemic control. Acarbose lowers blood glucose when administered as monotherapy and in combination with other oral antidiabetic drugs. It reliably reduces levels of glycated haemoglobin (HbA1c) and also increases insulin sensitivity; however, unlike insulin and the sulphonylureas, acarbose has not been associated with bodyweight gain.

The aim of this review is to present clinical data on the pharmacology and efficacy of acarbose in the treatment of patients with type 2 diabetes mellitus. It is not intended to present a comprehensive review of the treatment of diabetes mellitus in general.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II

Similar content being viewed by others

Notes

  1. 1Use of tradenames is for product identification only and does not imply endorsement.

References

  1. Campbell IW: Type 2 diabetes mellitus: the silent killer. Pract Diab Int 2001; 18(6): 187–91

    Article  Google Scholar 

  2. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86

    Article  Google Scholar 

  3. UK Prospective Diabetes Study Group, UK prospective diabetes study 16: overview of 6 years therapy of type 2 diabetes: a progressive disease. Diabetes 1995; 44: 1249–58

    Article  Google Scholar 

  4. Ohkubo Y, Kishikawa H, Araki E. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non insulin dependent diabetes mellitus: a randomized prospective 5-year study. Diabetes Res Clin Pract 1995; 28: 103–17

    Article  PubMed  CAS  Google Scholar 

  5. Müller L. Microbial glycosidase inhibitors. Biotechnology 1985; 4(18): 2–37

    Google Scholar 

  6. Mertes G. Efficacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2-year surveillance study. Diabetes Res Clin Pract 1998; 40: 63–70

    Article  PubMed  CAS  Google Scholar 

  7. Mertes G: Safety and efficacy of acarbose in the treatment of type 2 diabetes. Data from a 5-year surveillance study. Diabetes Res Clin Pract 2001; 52: 193–204

    Article  PubMed  CAS  Google Scholar 

  8. Hara T, Sakakibara F, Nakamura J, et al. An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM. Diabetes Care 1996; 19(6): 642–7

    Article  PubMed  CAS  Google Scholar 

  9. Wolever TMS, Chiasson JL, Josse RG, et al. No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30–60% of energy from carbohydrate. Diabetes Care 1998; 21: 1612–8

    Article  PubMed  CAS  Google Scholar 

  10. Lindström J, Tuomilehto J, Spenglert M. Acarbose treatment does not change the habitual diet of patients with type 2 diabetes mellitus. Diabet Med 2000; 17: 20–5

    Article  PubMed  Google Scholar 

  11. Costa B, Pinol C. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure; a randomised multicentric trial in primary health care. Diabetes and Acarbose Research Group. Diabetes Res Clin Pract 1997; 38(1): 33–40

    Article  PubMed  CAS  Google Scholar 

  12. Fölsch UR, Schwamen EV, Graf S, et al. Influence of long-term intake of a glycoside hydrolyse inhibitor on pancreatic exocrine secretion and contents of intestinal brush-border enzymes. Gastroenterol Clin Biol 1979; 3: 286–7

    Google Scholar 

  13. Lebowitz HE. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Review 1998; 6(2): 132–45

    Google Scholar 

  14. Caspary WF. Pathophysiology and clinical aspects of the malabsorption syndrome. In: Structure and function of the small intestine. Caspary WF, editor. Amsterdam: Excerpta Medica, 1987, 47

  15. May C. Efficacy and tolerability of stepwise dosage of acarbose in patients with non-insulin-dependent diabetes (NIDDM) treated with sulfonylureas. Diabetes u. Stoffwechsel 1995; 4: 3–7

    Google Scholar 

  16. Müting D. Acarbose bei der Behandlung von Diabetikern mit gleichzeitiger Leberzirrhose. Therapiewoche 1984; 34: 2566–72

    Google Scholar 

  17. Scheppach W, Fabian C, Ahrens F, et al. Effect of starch malabsorption on colonic function and metabolism in humans. Gastroenterology 1988; 95: 1549–55

    PubMed  CAS  Google Scholar 

  18. Morgan MY, Alonso M, Stanger LC. Lactitol and lactulose for the treatment of subclinical encephalopathy in cirrhotic patients. A randomised, cross-over study. J Hepatol 1989; 8: 208–17

    Article  PubMed  CAS  Google Scholar 

  19. Zillikens MC, Swart GR, Van den Berg JWO, et al. Effects of glucosidase inhibitor acarbose in patients with liver cirrhosis. Aliment Pharmacol Ther 1989; 3: 453–9

    Article  PubMed  CAS  Google Scholar 

  20. Holt H, Weiderpass E, Gridley G, et al. Diabetes mellitus and risk of large bowel cancer. J Natl Cancer Inst 1997; 89: 660–1

    Article  Google Scholar 

  21. Bloomgarden ZT. The European Association for the Study of Diabetes. Annual Meeting, 1998. Diabetes Care 1999; 22:(7) 1209–15

    PubMed  CAS  Google Scholar 

  22. Ahr HJ, Boberg M, Krause HP, et al. Pharmacokinetics of acarbose. Arzneimittelforschung 1989; 39: 1254–60

    PubMed  CAS  Google Scholar 

  23. Salehi A, Panagiotidis G, Hakan Borg LA, et al. The pseudotetrasaccharide acarbose inhibits pancreatic islet glucan-1, 4-α-glucosidase activity in parallel with a suppressive action on glucose-induced insulin release. Diabetes 1995; 44: 830–6

    Article  PubMed  CAS  Google Scholar 

  24. Zhang TM, Malaisse WJ. Acarbose internalisation in pancreatic islet cells. Med Sci Res 1994; 22: 479–80

    Google Scholar 

  25. Laube H, Aubell R, Schmitz H, et al. Acarbose an effective therapy in lowering postprandial hyperglycemia in obese patients with type-II diabetes mellitus. In: Creutzfeld W, editor. Proceedings of the First International Symposium on Acarbose; Excerpta Medica, Amsterdam, 1982: 344–7

    Google Scholar 

  26. Toeller M: Modulation of intestinal glucose absorption: postponement of glucose absorption by alpha-glucosidase inhibitors. In: Mogensen CE, Standl E, editors. Pharmacology of Diabetes. Berlin: de Gruyter, 1991: 93–11227

    Google Scholar 

  27. Hasche H, Mertes G, Bruns C, et al. Effects of acarbose treatment in type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study. Diabetes Nutr Metab 1999; 12: 277–85

    PubMed  CAS  Google Scholar 

  28. Baron A, Neumann C, PROTECT Study Group. PROTECT interim results: a large multicenter study of patients with type II diabetes. Clin Ther 1997; 19(2): 282–95

    Article  PubMed  CAS  Google Scholar 

  29. Coniff RF, Shapiro JA, Robbins D, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care 1995; 18: 817–24

    Article  PubMed  CAS  Google Scholar 

  30. Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732–7

    Article  PubMed  CAS  Google Scholar 

  31. Tuomilehto J. Acarbose monotherapy in treatment of non-insulin-dependent diabetes mellitus. A review. In: Creutzfeldt W, editor. Proceedings of the Second International Symposium on Acarbose; 1987. Berlin Springer Verlag, Berlin, Heidelberg, New York, London, 1988: 105–16

    Google Scholar 

  32. Goto Y, Toyoda T, Oikawa S, et al. Long term administration of BAY g 5421 (acarbose) in NIDDM. Yakuri to Chiro 1989; 17: 77–83

    Google Scholar 

  33. Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46(6): 1025–54

    Article  PubMed  CAS  Google Scholar 

  34. Meneilly GS, Ryan EA, Radziuk J. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000; 23(8): 1162–7

    Article  PubMed  CAS  Google Scholar 

  35. Seifarth C, Bergmann Y, Nauck M, et al. Prolonged and enhanced secretion of glucagon like peptide-1 (7–36 amide) after oral sucrose due to alpha glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabet Med 1998; 15: 485–91

    Article  PubMed  CAS  Google Scholar 

  36. Holman RR, Cull C, Turner R, et al. Acarbose improves control over three years in type 2 diabetes. Diabetes 1998; 47Suppl 1: A93

    Google Scholar 

  37. Hoffmann J, Spengler M. The Essen I Study: efficacy of 24 week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. Diabetes Care 1994; 17(6): 561–6

    Article  PubMed  CAS  Google Scholar 

  38. Salman S, Salman F, Satman I, et al. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Curr Med Res Opin 2001; 16(4): 296–306

    Article  PubMed  CAS  Google Scholar 

  39. Uttenthal LO, Ukponmwan OO, Wood SM, et al. Long term effects of intestinal alpha-glucosidase inhibition on postprandial glucose, pancreatic and gut hormone response and fasting serum lipids in diabetics on sulfonylureas. Diabet Med 1986; 3: 155–60

    Article  PubMed  CAS  Google Scholar 

  40. Hillebrand I, Boehme K, Frank G, et al. The effects of alpha-glucosidase inhibitor BAY g 5421 (acarbose) on meal stimulated elevations of circulating glucose, insulin and triglyceride level in man. Res Exp Med (Berl) 1979; 175: 81–6

    Article  CAS  Google Scholar 

  41. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994; 121(12): 928–35

    PubMed  CAS  Google Scholar 

  42. Reaven GM, Lardinois CK, Greenfield MS, et al. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 1990; 13Suppl 3: 32–6

    PubMed  Google Scholar 

  43. Wolever Th, Singer W, Chiasson JL, et al. Acarbose improves abnormal insulin metabolism in type 2 diabetics. Clin Res 1993; 41(2): 360 A

    Google Scholar 

  44. Lindstrom J, Tuomilehto J, Spengler M: The effect of acarbose on dietary nutrient intake and metabolic control in NIDDM patients. Diabetologia 1996; 39Suppl 1: 739

    Google Scholar 

  45. Sachse G, Mäser E, Laube H, et al. Diabetische Stoffwechsellage unter langffristiger Acarbosetherapie. Therapiewoche 1982; 32: 3587–90

    Google Scholar 

  46. William-Olsson T, Krotkiewski M, Sjöström L: Relapse-reducing effects of acarbose after weight reduction in severely obese subjects. Journal of Obesity and Weight Regulation 1985; 4: 20–32

    Google Scholar 

  47. Braun D, Schönherr U, Mitzkat HJ. Efficacy of acarbose monotherapy in patients with type 2 diabetes: a double-blind study conducted in general practice. Endocrinology and Metabolism 1996; 3: 275–80

    CAS  Google Scholar 

  48. Gutzwiller JR Glucagon like peptide-1 is a physiologic regulator of food intake in humans. Gastroenterology 1997; 112: A1153

    Google Scholar 

  49. Haffner SM, Flücker K, Hanefeld M, et al. Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM. Diabetes Care 1997; 20(9): 1430–4

    Article  PubMed  CAS  Google Scholar 

  50. Shinozaki K, Suzuki M, Ikebuchi M, et al. Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor in non-diabetic hyperinsulinemic subjects. Metabolism 1996; 45: 731–7

    Article  PubMed  CAS  Google Scholar 

  51. Chiasson JL, Josse RG, Leiter LA, et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19: 1190–3

    Article  PubMed  CAS  Google Scholar 

  52. Laube H, Linn Th, Heyen P. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes 1998; 106: 231–33

    Article  PubMed  CAS  Google Scholar 

  53. Calle-Pascual A, Garcia-Honduvilla J, Martin-Alvarez PJ, et al. Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo. Diabetes Metab 1996; 22: 201–2

    PubMed  CAS  Google Scholar 

  54. Jenney A, Proietto J, O’Dea K, et al. Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity. Diabetes Care 1993; 16: 499–502

    Article  PubMed  CAS  Google Scholar 

  55. Schnack C, Prager RJF, Winkler J, et al. Effect of 8 week alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output and peripheral insulin sensitivity in poorly controlled type 2 diabetic patients. Diabetes Care 1989; 12: 537–43

    Article  PubMed  CAS  Google Scholar 

  56. Holman RR, Turner RC, Cull CA, et al. A randomised double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 1999; 22(6): 960–4

    Article  PubMed  CAS  Google Scholar 

  57. Qualmann C, Nauck MA, Holst JJ, et al. Glucagon-like peptide 1 (GLP-1) (17–36 amide) secretion in response to luminal sucrose from the upper and lower gut: a study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995; 30: 892–6

    Article  PubMed  CAS  Google Scholar 

  58. Nauck MA, Holst JJ, Willms B, et al. Glucagon-like-peptide 1 (GLP-1) as a new therapeutic approach for type 2 diabetes. Exp Clin Endocrinol Diabetes 1997; 105: 187–95

    Article  PubMed  CAS  Google Scholar 

  59. Göke B, Herrmann C, Göke R, et al. Intestinal effects of alpha-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. Eur J Clin Invest 1994; 24Suppl 3: 25–30

    PubMed  Google Scholar 

  60. Requejo F, Uttenthal LO, Bloom SR. Effect of alpha-glucosidase inhibition and viscous fibre on diabetic control and postprandial gut hormone responses. Diabet Med 1990; 7: 515–20

    Article  PubMed  CAS  Google Scholar 

  61. Nestel PJ, Bazelmans J, Reardon MF, et al. Lower triglyceride production during carbohydrate-rich diets trough acarbose, a glucoside hydrolase inhibitor. Diabete Metab 1985; 11: 316–7

    PubMed  CAS  Google Scholar 

  62. Clissold SP, Edwards C. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1988; 35: 214–43

    Article  PubMed  CAS  Google Scholar 

  63. Zavaroni I, Reaven GM. Inhibition of carbohydrate-induced hypertriglyceridemia by a disaccharidase inhibitor. Metabolism 1981; 30: 417–20

    Article  PubMed  CAS  Google Scholar 

  64. Malaguarnera M, Giugno I, Ruello P, et al. Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridaemias. Br J Clin Pharmacol 1999; 48: 605–9

    Article  PubMed  CAS  Google Scholar 

  65. Malaguarnera M, Giugno I, Panebianco MP, et al. Beneficial effects of acarbose on familiar hypertriglyceridemias. Int J Clin Pharmacol Ther 1998; 36(8): 441–5

    PubMed  CAS  Google Scholar 

  66. Maruhama Y, Sasaki M, Ninomiya K, et al. The efficacy of acarbose on hyperinsulinemia and hyperlipidemia in overweight patients. Clinical Report 1995; 29(3): 172–80

    Google Scholar 

  67. Baron AD, Eckel RH, Schmeiser L, et al. The effect of short term alpha glucosidase inhibition on carbohydrate and lipid metabolism in type-2-diabetics. Metabolism 1987; 36: 409–15

    Article  PubMed  CAS  Google Scholar 

  68. Kado S, Murakami T, Aoki A, et al. Effect of acarbose on postprandial metabolism in type 2 diabetes mellitus. Diab Res Clin Pract 1998; 41: 49–55

    Article  CAS  Google Scholar 

  69. Homma Y, Irie N, Yano Y, et al. Changes in plasma lipoprotein levels during medication with a glucoside-hydrolase inhibitor (acarbose). Tokai J Exp Clin Med 1982; 7: 393–6

    PubMed  CAS  Google Scholar 

  70. Maruhama Y, Nagasaki A, Kanazawa Y, et al. Effects of glucoside hydrolase inhibitor (Bay g 5421) on serum lipids, lipoproteins and bile acids, faecal fat and bacterial flora, and intestinal gas production in hyperlipidemic patients. Tohoku J Exp Med 1980; 132: 453–62

    Article  PubMed  CAS  Google Scholar 

  71. Shimoyama T, Hori S, Tamura K, et al. Effects of acarbose on faecal microflora of hyperlipidemic patients. In: Creutzfelddt W, editor. Proceedings of the First International Symposium on Acarbose; Oct 1981, Montreux Excerpta Medica, Amsterdamn 1982: 461–70

    Google Scholar 

  72. Leonhardt W, Hanefeld M, Fischer S, et al. Beneficial effects on serum lipids in noninsulin-dependent diabetics by acarbose treatment. Arzneimittelforschung 1991; 41: 735–8

    PubMed  CAS  Google Scholar 

  73. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin or placebo in dietary-treated NIDDM patients: The Essen-II Study. Am J Med 1997; 103: 483–90

    Article  PubMed  CAS  Google Scholar 

  74. Couet C, Ulmer M, Hamdaoui M, et al. Metabolic effects of acarbose in young healthy men. Eur J Clin Nutr 1989; 43: 187–96

    PubMed  CAS  Google Scholar 

  75. Tulp OL, Abdollahi A, Stevens C, et al. The effects of the intestinal glucosidase inhibitor acarbose on cholesterologenesis in corpulent rats. Comp Biochem Physiol A 1991; 100(3): 763–8

    Article  PubMed  CAS  Google Scholar 

  76. Rosenthal J, Mauersberger H. Hypertension in type 2 diabetic patients -effects of endogenous insulin and antidiabetic therapies. Am J Hypertens 2000; 13: 81A

    Article  Google Scholar 

  77. Ceriello A, Taboga C, Tonutti L, et al. Post meal coagulation in diabetes mellitus: the effect of acarbose. Diabetologia 1996; 39: 469–73

    Article  PubMed  CAS  Google Scholar 

  78. Ridker PM, Hennekens CH, Cerskus A, et al. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236–40

    Article  PubMed  CAS  Google Scholar 

  79. The Cochrane Controlled Trial Register. In: The Cochrane Library, Issue 1, 2001; Oxford. Update Software, Updated quarterly [online]. Available from URL: http://www.update-software.com(zuletztwww.update-software.com [Accessed 2001 Mar 21]

  80. Santeusanio F, Ventura MM, Contadinbi S, et al. Efficacy and safety of two different dosages of acarbose in non-insulin dependent diabetic patients treated by diet alone. Diabetes Nutr Metab 1993; 6: 147–54

    Google Scholar 

  81. Fischer S, Hanefeld M, Spengler M, et al. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol 1998; 35: 34–40

    Article  PubMed  CAS  Google Scholar 

  82. Hollander PA. Safety profile of acarbose, an alpha glucosidase inhibitor. Drugs 1993; 44Suppl 2: 47–53

    Google Scholar 

  83. Harrower ADB, Harrower A, Jack H. Effect of fiber intake and meal pattern on gastrointestinal symptoms with acarbose. Diabetes Care 1999; 22(7): 1227

    Article  PubMed  CAS  Google Scholar 

  84. Spengler M, Hobler H, Cagatay M. Long-term tolerability of acarbose. In: Lefèbvre PJ, Standl E, editors. New aspects in diabetes. Treatment strategies with alpha-glucosidase inhibitors. De Gruyter, Berlin: 1992: 286–88

    Google Scholar 

  85. Rosak CH, Haupt E, Walter TH, et al. Alteration of insulin secretion and blood glucose course under glibenclamide by acarbose in type 2 diabetic patients: additive blood glucoselowering effect and reduced risk for hypoglycemia. Diabetes 2000; 49(Suppl 1): A348

    Google Scholar 

  86. Gentile S, Turco S, Guarino G, et al. Aminotransferase activity and acarbose treatment in patients with type-2 diabetes. Diabetes Care 1999; 22(7): 1217

    Article  PubMed  CAS  Google Scholar 

  87. Ben-Am H, Krivo N, Nagachandran P, et al. An interaction between digoxin and acarbose. Diabetes Care 1999; 22(5): 860–1

    Article  Google Scholar 

  88. Gérard J, Lefèbvre PJ, Luyckx AS. Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics. Eur J Clin Pharmacol 1984; 27: 233–6

    Article  PubMed  Google Scholar 

  89. Hillebrand I, Graefe KH, Bischoff H, et al. Serum digoxin and propanolol levels during acarbose treatment. Diabetologia 1981; 21: 282

    Google Scholar 

  90. Halimi S, Le Berre MA, Grangè V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: a double-blind placebo-controlled study. Diabetes Res Clin Pract 2000; 50: 49–56

    Article  PubMed  CAS  Google Scholar 

  91. Coniff RF, Shapiro JA, Seaton TB. Long term efficacy of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med 1994; 154(21): 2442–8

    Article  PubMed  CAS  Google Scholar 

  92. Coniff RF, Shapiro TB, Hoogwerf BJ, et al. A double blind placebo controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin requiring type 2 diabetes. Diabetes Care 1995; 18: 928–32

    Article  PubMed  CAS  Google Scholar 

  93. Kovacevic I, Profozic V, Skrabalo Z, et al. Multicentric clinical trial to assess efficacy and tolerability of acarbose in comparison to glibenclamide and placebo. Diabetologia Croatica 1997; 26(2): 83–9

    Google Scholar 

  94. Hotta N, Kakuta H, Sano T, et al. Long term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus. A placebo-controlled double-blind study. Diabet Med 1993; 10: 134–8

    Article  PubMed  CAS  Google Scholar 

  95. Kelley DE, Schimel D, Bidot P, et al. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care 1998; 21(12): 2056–61

    Article  PubMed  CAS  Google Scholar 

  96. Rosenstock J, Nadean D, Brown A, et al. Efficacy and safety of acarbose in metformin treated patients with Type 2 Diabetes. Diabetes Care 1998; 21: 2050–5

    Article  PubMed  CAS  Google Scholar 

  97. Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulfonylureas: a randomised, placebo-controlled study. Diabet Med 1999; 16: 755–61

    Article  PubMed  CAS  Google Scholar 

  98. Rybka J, Gregorová A, Zymdlena A, et al. Klinische Studie mit Acarbose. Drug Invest 1990; 2(4): 264–7

    Article  Google Scholar 

  99. Pinol C, Guardiola E, Soler J, et al. A double blind, randomised, placebo controlled study to assess the maximum insulin dose reduction achieved with acarbose in the treatment of insulin-requiring type 2 diabetic patients. Diabetes Nutr Metab 1998; 11: 242–8

    CAS  Google Scholar 

  100. Güvener N, Gedik O. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. Acta Diabetol 1999; 36: 93–7

    Article  PubMed  Google Scholar 

  101. Juntti-Berggren L, Pigon J, Holst JJ, et al. Influence of acarbose on postprandial insulin requirements in patients with type 1 diabetes. Diabetes Nutr Metab 2000; 13: 7–12

    PubMed  CAS  Google Scholar 

  102. Dimitriadis G, Karaiskos C, Raptis S. Effects of prolonged (6 months) alpha glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin dependent diabetes mellitus. Horm Metab Res 1986; 18: 253–5

    Article  PubMed  CAS  Google Scholar 

  103. Tattersal R. Alpha glucosidase inhibition as an adjunct to the treatment of type 1 diabetes. Diabet Med 1993; 10: 688–93

    Article  Google Scholar 

  104. Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type 1 diabetes. Diabetes Care 1997; 20(3): 248–53

    Article  PubMed  CAS  Google Scholar 

  105. Sailer D, Gossner L, Schönfuss I. Einfluss von Acarbose auf den Spritz-Eßabstand beim Typ1 Diabetes. Fortschr Med 1992; 110: 479–80

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Medizinische Klinik III/Poliklinik, Universität Giessen, Rodthohl 6, D-35385, Giessen, Germany

    Heiner Laube

Authors
  1. Heiner Laube
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heiner Laube.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laube, H. Acarbose. Clin. Drug Investig. 22, 141–156 (2002). https://doi.org/10.2165/00044011-200222030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200222030-00001

Keywords

Search

Navigation